# Asymchem Laboratories (Tianjin)

> Asymchem Laboratories (Tianjin) is a VC fund backing Pharmaceutical. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tianjin, China
- Total investments: 3
- Last investment: Aug 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/asymchem
- Website: http://www.asymchem.com
- Facebook: https://www.facebook.com/p/Asymchem-Laboratories-100068397146024/

Asymchem Laboratories (Tianjin) is a VC fund in Tianjin focused on Pharmaceutical and Biopharma. American company Asymchem Laboratories, Inc is the owner of Asymchem Laboratories (Tianjin) Inc. (凯莱英医药化学（天津）有限公司) , a company focused on the research and development of the pharmaceutical raw materials synthesis technology which is applied to drug development, production, and is also used in large and medium-sized pharmaceutical companies inEurope and America.Asymchem Laboratories (Tianjin) Inc. owns more than 400 independent synthetic techniques and nearly 3500 products. In addition, all the major technical leaders and management personnel of the company have the experience of working in large and medium-sized pharmaceutical companies and American universities. Asymchem Laboratories (Tianjin) Inc was founded in 1998.

## Contacts

5 contacts available for Asymchem Laboratories (Tianjin). Shizune tracks 4 team members at Asymchem Laboratories (Tianjin). Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/asymchem-laboratories-tianjin?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Pharmaceutical | 3 | 100% |
| Biopharma | 2 | 67% |
| Life Science | 2 | 67% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Private Equity | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 67% |
| United States | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Cheng Yi Chen | Chief Technology Officer | 0 | — |
| Hao Hong | Founder, CEO and Chairman | 0 | — |
| James Gage | Chief Scientific Officer and SVP of Chemical Development | 0 | — |
| Rui Yang | Chief Operating Officer | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AsymBio | AsymBio is a biopharmaceutical contract development and manufacturing organization focused on biologics and bioconjugates. It provides integrated services spanning R&D, developability assessment, process optimization, CMC, analytical science, quality control, regulatory affairs, and cGMP manufacturing. The company specializes in antibodies,recombinant biotherapeutics, antibody-drug conjugates and other novel drug conjugates, bioconjugates, and mRNA. AsymBio supports programs from early-stage development through late-stage clinical and commercial production using single-use bioreactors, fill-finish lines, and large-scale manufacturing bases. | $183.6M | Private Equity | Aug 04, 2026 |  |
| Bio-Link | Bio-Link is a drug development company that offers solutions for the life science industry. Bio-Link was founded in 2001 and was headquartered in Shanghai, China. |  | Series A | Feb 21, 2024 |  |
| LaNova Medicines | LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs. |  | Series A | Sep 16, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Bloomage Healthcare Consumer Goods Industry Fund](https://shizune.co/investors/profile/bloomage-healthcare-consumer-goods-industry-fund) — VC Fund, 1 deal together
- [Bridge Hill Capital](https://shizune.co/investors/profile/bridge-hill-capital) — VC Fund, 1 deal together
- [Cathay Capital](https://shizune.co/investors/profile/cathaycapital) — VC Fund, 1 deal together
- [CTS Capital](https://shizune.co/investors/profile/cts-capital) — VC Fund, 1 deal together
- Haiwang Capital — VC Fund, 1 deal together
- [Hillhouse Capital](https://shizune.co/investors/profile/hillhouse-capital-a4ff) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Asymchem Laboratories (Tianjin) invest in?

Asymchem Laboratories (Tianjin) invests primarily in Pharmaceutical, Biopharma and Life Science startups, most often at Series A and Private Equity stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Asymchem Laboratories (Tianjin)?

Public channels for Asymchem Laboratories (Tianjin) include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Asymchem Laboratories (Tianjin)?

The team at Asymchem Laboratories (Tianjin) includes Cheng Yi Chen (Chief Technology Officer), Hao Hong (Founder, CEO and Chairman) and James Gage (Chief Scientific Officer and SVP of Chemical Development). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co